Jingyi Wang

Ms. Jingyi Wang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2024 in International Journal of Surgery
Verified
Journal Article
Open access
YLYangguang Lu
Yangguang Lu
YYYingyu Yao
Yingyu Yao
SZSijia Zhai
Sijia Zhai
FNFeitian Ni
Feitian Ni
JWJingyi Wang
Jingyi Wang
DLDi Lu
Di Lu
Background: Immune cells play a pivotal role in maintaining ovarian function. However, the specific contributions of different immune cell phenotypes to the pathogenesis of specific ovarian-related diseases remain poorly understood. The authors aim to investigate the correlation between 731 immunophenotypes and ovarian-related diseases. Materials and methods: Utilizing publicly available genetic data, the authors undertook a series of quality control measures to identify instrumental variables associated with exposure. Subsequently, we conducted two-sample Mendelian randomization (MR) using inverse variance weighting to explore the causal relationships between 731 immune cell features and six ovarian-related diseases: ovarian cysts, ovarian dysfunction, premature ovarian failure (POF), polycystic ovary syndrome (PCOS), benign neoplasm of ovary, and malignant neoplasm of ovary at the genetic level. Sensitivity analyses, including leave-one-out and other MR analysis models, were performed. Finally, Bayesian colocalization (COLOC) analysis was employed to identify specific co-localized genes, thereby validating the MR results. Results: At the significance level corrected by Bonferroni, four immune phenotypes, including CD25 on IgD- CD38- B cells, were associated with ovarian cysts; four immune phenotypes, including CD39+ CD4+ T cell Absolute Count, were associated with ovarian dysfunction; eight immune phenotypes, including SSC-A on HLA DR+ CD8+ T cells, were associated with POF; five immune phenotypes, including CD20- CD38- B cell Absolute Count, were associated with PCOS; five immune phenotypes, including CD4+ CD8dim T cell Absolute Count, were associated with benign ovarian tumors; and three immune phenotypes, including BAFF-R on IgD- CD38+ B cells, were associated with malignant ovarian tumors. Sensitivity analysis indicated robust results. COLOC analysis identified four immune cell co-localized variants (rs150386792, rs117936291, rs75926368, and rs575687159) with ovarian diseases. Conclusion: Our study elucidates the close genetic associations between immune cells and six ovarian-related diseases, thereby providing valuable insights for future research endeavors and clinical applications.

30 August 2024 in Cancer Letters
Verified
Journal Article
Open access
BLBorui Li
Borui Li
FXFaliang Xing
Faliang Xing
JWJingyi Wang
Jingyi Wang
XWXiaohong Wang
Xiaohong Wang
CZChenjie Zhou
Chenjie Zhou
ZLZheng Li
Zheng Li
Pancreatic ductal adenocarcinoma (PDAC) is highly malignant and has a poor prognosis, without effective therapeutic targets in common gene mutations. Gemcitabine, a first-line chemotherapeutic for PDAC, confers <10 % 5-year survival rate because of drug resistance. Y-box binding protein 1 (YBX1), associated with multidrug-resistance gene activation, remains unelucidated in PDAC gemcitabine resistance. In vivo and in vitro, we verified YBX1's promotional effects, especially gemcitabine resistance, in pancreatic cancer cells. YBX1-induced LRP1 transcription by binding to the LRP1 promoter region significantly altered the concentration and distribution of β-catenin in pancreatic cancer cells. Through TCF3, β-catenin bound to the promoter region of RRM1, a key gene for gemcitabine resistance, that promotes RRM1 expression. Combination therapy with the YBX1 inhibitor SU056 and gemcitabine effectively reduced gemcitabine resistance in in vivo and in vitro experiments. High YBX1 expression promoted pathogenesis and gemcitabine resistance in pancreatic cancer through the YBX1-LRP1-β-catenin-RRM1 axis. Combining YBX1 inhibitors with gemcitabine may provide a new direction for combination chemotherapy to overcome gemcitabine resistance, which frequently occurs during chemotherapy for pancreatic cancer.

26 July 2024 in Biomacromolecules
Verified
Journal Article
Closed access
DZDayong Zhang
Dayong Zhang
BSBing Sun
Bing Sun
JWJingyi Wang
Jingyi Wang
SCSung-Po Chen
Sung-Po Chen
VBValentin A. Bobrin
Valentin A. Bobrin
Michael J MonteiroMichael J Monteiro
Michael J Monteiro

27 April 2026 in Cells
Verified
Journal Article
Open access
PDF file
MLMan Pok Lu
Man Pok Lu
YRYi Rong
Yi Rong
JWJingyi Wang
Jingyi Wang
XYXiaochun Yu
Xiaochun Yu
HLHongjiang Liu
Hongjiang Liu
ZLZHAOYU LI
ZHAOYU LI
Tau hyperphosphorylation is a hallmark of tauopathies and is closely associated with neurodegeneration. While targeting kinases and phosphatases to suppress tau phosphorylation has become an increasingly attractive therapeutic approach, the functional significance of tau phosphorylation and the potential risks of suppressing this process are not fully understood. Using C. elegans, we introduced non-phosphorylatable tau mutations (hTauAP) to model the suppression of tau phosphorylation. Unexpectedly, we found that hTauAP induced severe neurotoxicity, resulting in behavioural deficits and severe neurite abnormalities. This neurotoxicity is associated with excessive accumulation of hTauAP on microtubules, leading to both neurite developmental defects and adult neurite degeneration. The neurotoxic effects of hTauAP require its microtubule-binding domain (MTB) and are primarily driven by the loss of phosphorylation in the C-terminal region (CTR). Removing either domain reduces microtubule association and suppresses toxicity. Within CTR, suppressing phosphorylation at S396 or S404 is critical for neurotoxicity. These findings highlight the essential role of tau phosphorylation in neuronal function and underscore the potential risks of broadly suppressing tau phosphorylation as a therapeutic strategy.